Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 2853-2861

  Klyushnenkova, Elena N ^a   Link, Jason ^b,c,d   Oberle, Warren T ^a   Kodak, James ^a   Rich, Cathleen ^b,c,d   Vandenbark, Arthur A ^b,c,d   Alexander, Richard B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FREUND ADJUVANT; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PEPTIDE LIBRARY; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CHRONIC PROSTATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; GRANULOMATOSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; MALE; MOLECULAR RECOGNITION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-DR ANTIGENS; HLA-DR2 ANTIGEN; HUMANS; INTERFERON TYPE II; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN;

EID: 17144420098     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1927     Document Type: Article

References (23)

1. Ostrand-Rosenberg S, Pulaski BA, Clements VK, et al. Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev 1999;170:101-14.
2. Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997;30:73-8.
3. Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxicT lymphocytes specific for peptides derived from prostate-specific antigen. Journal of the National Cancer Institute 1997;89:293-300.
4. Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 Tcells. Clin Exp Immunol 1998;114:166-72.
5. Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate 2003;57:152-9.
6. Alexander RB, Brady F, Leffell MS, Tsai V, Cells E. Specific T cell recognition of peptides derived from prostate specific antigen in patients with prostatic cancer. Urology 1998;51:150-7
7. Alexander RB, Mann DL, Borkowski A, et al. Granulomatous prostatitis linked to HLA-DRB1*1501. J Urology 2004;171:2326-9.
8. Stillwell TJ, Engen DE, Farrow GM. The clinical spectrum of granulomatous prostatitis: a report of 200 cases. J Urol 1987;138:320-3.
9. Klyushnenkova EN, Ponniah S, Rodriguez A, et al. CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother 2004;27:136-46.
10. Rich C, Link JM, Zamora A, et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol 2004;34:1251-61.
11. Madsen LS, Andersson EC, Jansson L, et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999;23:343-7.
12. Woods A, Chen HY, Trumbauer ME, Sirotina A, Cummings R, Zaller DM. Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. J Exp Med 1994;180:173-81.
13. Vandenbark AA, Rich C, Mooney J, et al. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol 2003;171:127-33.
14. Madsen L, Labrecque N, Engberg J, et al. Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A 1999;96:10338-43.
15. Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 2001;101:276-83.
16. Kovats S, Drover S, Marshall WH, et al. Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome. J Exp Med 1994;179:2017-22.
17. Wu CH, Huang H, Arminski L, et al. The Protein Information Resource: an integrated public resource of functional annotation of proteins. Nucleic Acids Res 2002;30:35-7.
18. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001;17:1236-7.
19. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999;17:555-61.
20. Dummer R, Mittelman A, Fanizzi FP, Lucchese G, Willers J, Kanduc D. Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int J Cancer 2004;111:720-6.
21. Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000;44:49-54.
22. Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol 2004;172:5967-72.
23. Rosenberg SA, White DE. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19:81-4.